caa a22 4500 37885898X CHVBK 20180305123341.0 cr unu---uuuuu 161128e20031107xx s 000 0 eng 10.1515/BC.2003.168 doi (NATIONALLICENCE)gruyter-10.1515/BC.2003.168 Increase of Anti-Metastatic Efficacy by Selectivity- But Not Affinity-Optimization of Synthetic Serine Protease Inhibitors [Elektronische Daten] [I. J. Banke, M. J. E. Arlt, C. Pennington, C. Kopitz, T. Steinmetzer, A. Schweinitz, B. Gansbacher, J. P. Quigley, D. R. Edwards, J. Stürzebecher, A. Krüger] Although tumors frequently show elevated protease activities, the concept of anti-proteolytic cancer therapy has lost momentum after failure of clinical trials with broad-spectrum matrix metalloproteinase inhibitors. Thus we need to adapt our design strategies for protease inhibitors. Here, we employed a series of seven structurally fine-modulated and pharmacokinetically closely related synthetic 4-amidinobenzylamine based inhibitors with distinct selectivity for prototypical serine proteases in a murine T cell lymphoma liver metastasis model. This in vivo screening revealed efficacy of urokinase inhibitors but no correlation between urokinase selectivity or affinity and antimetastatic effect. In contrast, factor Xa-selective inhibitors were more potent, demonstrating factor Xa or a factor Xa-like serine protease likely to be more determinant in this model. Factor Xa selectivity, but not affinity, significantly improved antimetastatic efficacy. For example, factor Xa inhibitors CJ-504 and CJ-510 exert similar affinity for factor Xa (Ki=14 nM versus 8.8 nM) but CJ-504 was 70-fold more selective for factor Xa. This correlated with higher antimetastatic efficacy (58.8% with CJ-504; 28.2% with CJ-510). Our results show that among the protease inhibitors employed that have affinities in the nanomolar range, the strategy of selectivity-optimization is superior to further improvement of affinity to significantly enhance anti-metastatic efficacy. This appreciation may be important for the future rational design of new anti-proteolytic agents for cancer therapy. Copyright © 2003 by Walter de Gruyter GmbH & Co. KG Biochemistry nationallicence Molecular biology nationallicence Cellular biology nationallicence Banke I. J. aut Arlt M. J. E. aut Pennington C. aut Kopitz C. aut Steinmetzer T. aut Schweinitz A. aut Gansbacher B. aut Quigley J. P. aut Edwards D. R. aut Stürzebecher J. aut Krüger A. aut Biological Chemistry Walter de Gruyter 384/10-11(2003-11-07), 1515-1525 1431-6730 384:10-11<1515 2003 384 bchm https://doi.org/10.1515/BC.2003.168 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/BC.2003.168 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Banke I. J. aut NATIONALLICENCE 700 1- Arlt M. J. E. aut NATIONALLICENCE 700 1- Pennington C. aut NATIONALLICENCE 700 1- Kopitz C. aut NATIONALLICENCE 700 1- Steinmetzer T. aut NATIONALLICENCE 700 1- Schweinitz A. aut NATIONALLICENCE 700 1- Gansbacher B. aut NATIONALLICENCE 700 1- Quigley J. P. aut NATIONALLICENCE 700 1- Edwards D. R. aut NATIONALLICENCE 700 1- Stürzebecher J. aut NATIONALLICENCE 700 1- Krüger A. aut NATIONALLICENCE 773 0- Biological Chemistry Walter de Gruyter 384/10-11(2003-11-07), 1515-1525 1431-6730 384:10-11<1515 2003 384 bchm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter